Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors
Risks
Default risk
Data is available to registered users only
Volatility
Data is available to registered users only
Selling difficulty
Data is available to registered users only
Stress test
Data is available to registered users only
Country risks
Data is available to registered users only
Other risks
Data is available to registered users only
Sign up to access detailed risk analysis
About
Biomind Labs Inc. operates as a biotechnology firm dedicated to advancing innovative pharmaceutical therapies and sophisticated nanotech drug delivery mechanisms, primarily addressing a range of psychiatric and neurological disorders. Among its leading pipeline assets, BMND01 is currently in Phase II clinical trials for treating depression. Another key candidate, BMND08, a derivative of 5-Methoxy-N,N-dimethyltryptamine, is also in Phase II trials, addressing depression and anxiety specifically in patients experiencing cognitive decline associated with Alzheimer's disease. The company's broader development portfolio includes early-stage and preclinical candidates such as BMND02 for fibromyalgia, BMND03 for substance use disorders, BMND05 for persistent pain management, BMND06 for inflammatory conditions, and BMND07 for severe clinical depression. Biomind Labs Inc. maintains its headquarters in Canelones, Uruguay.